3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
242
Neoplasms, Plasma Cell
50
Lymphoma
45
Lymphoma, Mantle-Cell
40
Precursor Cell Lymphoblastic Leukemia-Lymphoma
31
Lymphoma, Non-Hodgkin
30
Recurrence
29
Lymphoma, Follicular
24
Leukemia, Myeloid, Acute
24
Lymphoma, Large B-Cell, Diffuse
23
Waldenstrom Macroglobulinemia
22
Lymphoma, B-Cell, Marginal Zone
20
Leukemia
20
Immunoglobulin Light-chain Amyloidosis
18
Leukemia, Lymphocytic, Chronic, B-Cell
14
Myelodysplastic Syndromes
12
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
11
Hodgkin Disease
11
Burkitt Lymphoma
10
Breast Neoplasms
10
Lymphoma, T-Cell, Peripheral
9
Lymphoma, Large-Cell, Anaplastic
9
Lymphoma, B-Cell
9
Lung Neoplasms
9
Immunoblastic Lymphadenopathy
9
Hematologic Neoplasms
9
Prostatic Neoplasms
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, T-Cell
8
Interventions
prednylidene
1
merphos
1
ixazomib
1
deltacortene
1
daratumumab
1
belantamab mafodotin
1
Vincristine
1
Rituximab
1
Prednisone
1
Methotrexate
1
Hydrocortisone
1
Etoposide
1
Doxorubicin
1
Dexamethasone
1
Cytarabine
1
Cyclophosphamide
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Plasmablastic Lymphoma
×
Bortezomib
×
Clear all
NCT04915248
2026-06-02
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Phase 2
Recruiting
28 enrolled